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Abstract The International Duration Evaluation of Adju-
vant Chemotherapy (IDEA) collaboration was established
to prospectively combine and analyze data from several
randomized trials conducted around the world to answer
whether a three-month course of oxaliplatin-based adjuvant
therapy (FOLFOX4/modified FOLFOX6 or XELOX) is
non-inferior to the current standard six-month treatment for
patients with stage III colon cancer, with a primary endpoint
of three years disease-free survival. The IDEA steering com-
mittee comprises two members from each group coordinat-
ing an individual trial and two members from a secretariat
who coordinate combining of the data and management of
the joint analysis. Members of the IDEA agreed to combine
the data from their individual trials to enable definitive
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analysis consisting of at least 10,500 patients. With accrual
of 8,797 patients at the end of February 2013, the IDEA is on
track to achieve its accrual objective of at least 10,500
patients by the end of 2013.
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Introduction
Six months of adjuvant chemotherapy with fluoropyrimidines
(5-fluorouracil and leucovorin (5-FU/LV) or capecitabine) and
oxaliplatin is the current worldwide standard of care for pa-
tients with stage III colon cancer, based on the findings from
three large trials—the Multicenter International Study of
Oxaliplatin/5-FU/LV in the Adjuvant Treatment of Colon
Cancer (MOSAIC), the National Surgical Adjuvant Breast
and Bowel Project (NSABP) C-07 trial, and the NO16968
study [1, 2••, 3, 4•, 5••, 6].
The MOSAIC randomized phase III trial compared the
efficacy of 5-FU/LV in combination with oxaliplatin
(FOLFOX4 regimen) with that of 5-FU/LV, for six months,
among patients with stage II and III colon cancer [1, 2••]. A
24% (HR=0.76, p=0.005) reduction in relative risk of relapse
was observed among stage III patients receiving FOLFOX4.
The updated results, published in 2009, revealed an advantage
in terms of five-year disease-free survival (DFS) for
FOLFOX4 (66.4 %) over 5-FU/LV (58.9 %; HR=0.78,
p=0.005) among patients with stage III colon cancer. Six-
year overall survival (OS) was 72.9 % for patients receiving
FOLFOX4 compared with 68.7 % for patients in the control
group (HR=0.80, p=0.023) [1, 2••]. The NSABP C-07 trial
compared the efficacy of oxaliplatin added to a weekly bolus
5-FU/LV regimen (FLOX) with that of bolus 5-FU/LV alone
(Roswell Park regimen). This study revealed a benefit of
oxaliplatin addition for stage III patients: five-year DFS was
64.4 % vs. 57.8 % (p<0.0007) and five-year OS was 76.5 %
vs. 73.8 %, HR=0.85 (p=0.052) [3, 4•]. A third study, the
NO16968 trial, compared a three-weekly capecitabine and
oxaliplatin regimen (XELOX) versus bolus 5-FU/LV (Mayo
Clinic or Roswell Park regimen) for stage III colon cancer and
showed a three-year DFS of 70.9 % with XELOX vs. 66.5 %
with 5-FU/LV (HR=0.80, p=0.0045). Similarly, a significant
improvement associated with XELOX on OS at seven years
was observed (73 % vs. 67 %, HR=0.83, p=0.0367) [5••, 6].
Results from these three positive adjuvant phase III trials
supported the survival benefit of adding oxaliplatin to
fluoropyrimidines in the adjuvant setting for patients with
stage III colon cancer [1, 2••, 3, 4•, 5••, 6].
Despite the efficacy of fluoropyrimidines and oxaliplatin-
based chemotherapy for patients with stage III colon cancer,
this treatment leads to significant cost, toxicity, and patient
inconvenience. In particular, oxaliplatin-induced cumulative
dose-dependent neurotoxicity is clinically relevant. In the
MOSAIC trial, the incidence of grade 3 neurotoxicity one
year after completion of treatment was estimated to be 12 %,
and grade 1 or 2 neurotoxicity in the second post-treatment
year was still affecting approximately 50% of patients [1, 2••].
In colon cancer the initial demonstration of efficacy of
adjuvant 5-FU plus levamisole was based upon 12 months of
treatment [7]. Thereafter, 6 months of 5-FU/LV proved to be
as effective as 12 months of 5-FU/levamisole. Subsequent
studies of the Intergroup trial 0089 (INT-0089) supported
equivalence of 6 months 5-FU/LV adjuvant chemotherapy
and 12 months 5-FU/levamisole treatment [8]. Furthermore,
the Groupe Cooperateur Multidisciplinaire en Oncologie
(GERCOR) trial showed that 6 months of the 5-FU/LV
regimen is as effective as 9 months of 5-FU/LV in the
adjuvant setting [9, 10].
Chau et al., conducted an adjuvant treatment trial of 801
patients with stage II and III colorectal cancer, and demon-
strated that three months of protracted venous infusion of 5-
FU is as effective as six months of standard bolus 5-FU/LV
and significantly less toxic [11]. Although the study was
designed as a superiority trial, the analysis conducted con-
cluded that the chances of the three-month regimen being
inferior to the six-month treatment plan were extremely low
(p<0.005). No other study has investigated the possibility of
further reducing the duration of the entire adjuvant chemo-
therapy below six months for patients with stage III colon
cancer. More recent data, however, provide additional argu-
ments supporting the plausibility of shorter duration treat-
ment without loss of efficacy.
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Two studies, the MOSAIC and NSABP C-07, provided
evidence in support of changing to shorter-duration FOLFOX
doublet-based treatment. In those two studies, the benefit of six
months FOLFOX treatment (MOSAIC) was identical with that
of FLOX regimen (NSABP C-07); the total dose of oxaliplatin
in the two studies differed by approximately 30 %. Moreover,
whereas the per-protocol planned oxaliplatin dose was
1,020 mg/m2 (12 cycles) in MOSAIC and 765 mg/m2 (nine
cycles) in C-07, the median oxaliplatin dose received per-
patient was 810mg/m2 (9.5 cycles) and 667mg/m2 (7.8 cycles)
in MOSAIC and C-07, respectively [1, 2••, 3, 4•].
In addition, a recent study of 2,560 colon cancer patients
who received adjuvant fluoropyrimidine and oxaliplatin ad-
juvant therapy between January 2004 and April 2010 at US
cancer care facilities participating in a nationwide, commer-
cially available chemotherapy order entry system showed
that 26.9 % of patients did not complete more than three
months of therapy [12].
The ability to maintain the efficacy of treatment with a
reduced duration of therapy would clearly be advantageous
to patients, health care providers, and health care systems. To
eliminate the possibility of clinically meaningful inferiority of
three months of therapy a large number of patients will be
necessary. Previous efforts and experience have conclusively
demonstrated that for colon cancer, a single, global trial is
impractical for answering the question of the duration of
adjuvant chemotherapy. Consequently, independent trials
worldwide are currently in progress to gather data and perform
a prospective combined analysis to answer the single primary
hypothesis that 3 months of adjuvant therapy with oxaliplatin-
based chemotherapy is non-inferior to the current standard of
six months for patients with stage III colon cancer.
Methods
To be included in the IDEA combined analysis all trials must
share a limited number of characteristics. Specific require-
ments include:
& enrolment of patients with stage III colon cancer;
& randomization of patients into a standard group with a
planned 12 treatments of FOLFOX (FOLFOX4 or mod-
ified FOLFOX6 (mFOLFOX6)) or eight treatments of
XELOX and an experimental group with planned six
treatments of FOLFOX (FOLFOX4 or mFOLFOX6) or
four cycles of XELOX;
& use of DFS at three years as primary endpoint;
& optimum stratification (recommended and optional) of
patients by clinical T-stage (T1/T2 vs. T3 vs. T4), perfor-
mance status (PS, 0 vs. 1 vs. 2), and age (<70 vs. ≥70); and
& agreement of the investigators to combine data for the
IDEA definitive analysis.
Each individual trial may contain additional, trial-specific
hypotheses in a factorial design, and may include other trial-
specific secondary aims, for example translational, quality of
life, health economic, and others. Finally, each trial may also
enable enrolment of patients with stage II colon cancer or
rectal cancer, but the IDEA combined analysis will consist
only of patients with stage III colon cancer enrolled in these
trials. To the extent possible, every effort will be made to keep
all trials included in IDEA as simple as possible in terms of
eligibility criteria and data collection. However, except for a
limited number of mandatory data items (Table 1), informa-
tion on individual trial follow-up and data collection will be
specific to each trial.
The following six trials are currently participating in the
IDEA project:
& the Italian Three or Six Colon Adjuvant (TOSCA) trial;
& the UK Short Course Oncology Treatment (SCOT) trial;
& the IDEA France trial;
& the intergroup Cancer and Leukemia Group B/Southwest
Oncology Group (CALGB/SWOG) trial 80702;
& the Greek Hellenic Oncology Research Group (HORG)
trial; and
& the Japanese Adjuvant Chemotherapy for colon cancer
with HIgh EVidencE (ACHIEVE) trial.
Four of these trials, the SCOT, IDEA France, Japanese
ACHIEVE, and HORG are addressing the single question of
the noninferiority of three months of oxaliplatin-based adju-
vant chemotherapy versus the current standard of six
months. The Italian TOSCA trial, in addition to the primary
question in its factorial design, also initially assessed wheth-
er the combination of bevacizumab with FOLFOX4 is supe-
rior to FOLFOX4 alone. The TOSCA randomization of
bevacizumab was closed after publication of results from
the NSABP C-08 study [13•]. The US Intergroup 80702
colon trial, in addition to randomization of three versus six
months, randomizes patients to three years of celecoxib or
placebo, both in combination with mFOLFOX6, in a 2×2
factorial design. The trial will test for superiority in DFS of
celecoxib compared with placebo. The IDEA collaboration
will not report its primary findings until all six included trials
have completed their accrual.
Chemotherapy
FOLFOX4
A two-hour infusion of LV 200 mg/m2 followed by a
400 mg/m2 bolus 5-FU followed by a 22-hour infusion of
5-FU 600 mg/m2 given on two consecutive days plus a two-
hour infusion of 85 mg/m2 oxaliplatin, on day 1, simulta-
neously with LV, using a Y-infusion device.
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mFOLFOX6
Oxaliplatin 85 mg/m2 intravenous (IV) infusion with LV
400 mg/m2 over two hours using a Y-infusion device, followed
by 400 mg/m2 bolus 5-FU followed by an IV infusion of 5-FU
2400 mg/m2 for 46 hours. (N.B. In the SCOT trial, the dose of
LV is fixed to 350 mg total dose.)
XELOX
Oxaliplatin 130 mg/m2 IV infusion over two hours (day
1 every three weeks) in combination with capecitabine
administered orally at a dose of 1000 mg/m2 twice-daily
(equivalent to a total daily dose of 2000 mg/m2, the first
evening dose on day 1 and the last morning dose on day
15) given as intermittent treatment (three-week cycles
consisting of two weeks of treatment followed by one
week without treatment).
Dose modification as a result of adverse events and tox-
icity is being conducted on the basis of standard clinical
practice unless specified in the individual protocols.
Data sharing
Data transfer from each individual trial to the IDEA
database will be coordinated individually with each trial
on the basis of local data-transfer restrictions and re-
quirements. It is expected that at least one annual report
on the number of DFS events in the two groups will be
submitted to IDEA to facilitate interim analysis. To
ensure data quality, and to monitor the number of
DFS events for the interim analysis, records (exclusively
de-identified data) from each individual trial will be
electronically transmitted to the IDEA secretariat. When
the primary analysis has been completed, a de-identified
dataset from the primary analysis will be made available
to all IDEA members. Each individual group will be
authorized to include or exclude their data from any
subsequent analysis proposed by IDEA members. The
data required for the IDEA combined analysis are in-
cluded in Table 1.
IDEA Steering Committee
The IDEA steering committee comprises two members
from each group coordinating an individual trial with
two members from a secretariat who will be responsible
for coordinating combination of the data and the joint
analysis. It is expected that the IDEA secretariat will be
independent of any of the groups that are leading the
individual trials.
IDEA Data and Safety Monitoring Board (DSMB)
The committee agreed to the establishment of an IDEA DSMB
to consider the results of the interim analysis. The committee
will review efficacy data only, because tolerability is not rele-
vant for the standard of care treatment. The IDEA DSMB
membership is composed of four members: the chairs of the
DSMBs of the TOSCA, SCOT, and CALGB/SWOG trials, and
a statistician. The IDEA DSMB will consider the confidential
results of the interim analysis and report the blinded outcome to
Table 1 Required data elements for the IDEA trials
Baseline data
Age in years at randomization (date of birth)
Baseline performance status
Sex (M/F)
Number of nodes positive/number of nodes examined
T stage (1, 2, 3, 4)
Obstruction (Y/N); perforation (Y/N)
Adherence (Y/N)
Histology: high grade (not or slightly differentiated)/low grade (moderately
or well differentiated)
Date of surgery, date of randomization
Eligibility status (Y/N)
Randomization group (3 or 6 months)
Ancillary randomization arm (if a 2×2 factorial design)
Treatment data
Date of first cycle of adjuvant treatment, date of last adjuvant cycle
Total number of two-week cycles delivered, total FU dose (in mg/m2),
Total oxaliplatin dose (in mg/m2)
Calcium and magnesium (Y/N)
Reason treatment protocol ended (completion per protocol,
adverse event, patient refusal, recurrence, other)
Adverse event data: worst grade experienced during the on-study period
(up to one month after last administration of chemotherapy):
Neutropenia (0 to 5), thrombocytopenia (0 to 5)
Diarrhea (0 to 5), nausea (0 to 5), vomiting (0 to 5)
Stomatitis (0 to 5)
Fatigue (0 to 5)
Neuropathy (0 to 4)—worst grade during or just after study
chemotherapy, i.e. within one month after the end of chemotherapy
Febrile neutropenia (0 to 5)
Allergy (0 to 5), other, specify (0 to 5)
Follow-up data (at each follow-up visit)
Date of follow-up visit neuropathy (Y/N, if yes, grade)
Recurrence status (Y/N)
If recurrence, date and site of recurrence
Vital status (Y/N)
If dead, date of death
If dead, cause of death (this cancer, other cancer, other, unknown)
Other second primary cancer (Y/N) – If yes, location.
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the IDEA steering committee. The IDEA Secretariat will con-
tract with an independent statistician to perform the analysis for
the IDEA DSMB.
Statistics
The primary efficacy variable for the IDEA combined anal-
ysis is DFS at three years, defined as the time from random-
ization to relapse or death, whichever occurred first. Second
colorectal cancers are regarded as DFS events, whereas non-
colorectal tumors are to be disregarded in the analysis.
The objective of IDEA is to combine data from several
clinical trials, each with individual planned sample sizes of a
minimum of 1000 patients, to ensure success in achieving at
least 10,500 patients for the combined analysis.
The IDEA primary efficacy analysis will estimate the hazard
ratio for DFS comparing three with six months of therapy using
a Cox proportional hazards regression model. As originally
planned, noninferiority was to be declared if the two-sided
95 % confidence interval for the hazard ratio comparing three
to six months of therapy lies entirely below 1.10. Individual
IDEA trials may also address additional study-specific hypoth-
eses; to protect the integrity of each individual trial, however,
these will not be included in the IDEA analysis. The primary
analysis will be modified intention to treat, including patients in
their randomized group, irrespective of the actual treatment or
duration of treatment received, with only patients who receive
no therapy whatsoever excluded from the analysis. This is to
avoid the potential bias of a conventional per-protocol analysis,
which may be typically considered for a noninferiority trial, in
that patients in the six month group who complete three or
fewer months of therapy may be a biased sub-group to include
with patients randomized to the three month arm as would be
done in a per-protocol analysis. Secondary analysis, however,
will investigate the effects of compliance with treatment dura-
tion. A sample size of 10,500 patients provides 90 % power,
based on expected accrual duration of 3.5 years, three years
minimum follow-up, and expected three-year DFS in the con-
trol group of 72 %. Given that this is a noninferiority trial and
there is no expectation of superior results for the reduced
duration therapy, an interim analysis to conclude noninferiority
will not be conducted. Two interim analyses for inferiority of
three months of therapy, at 50 % and 75 % of the protocol-
specified combined number of events, were initially planned.
IDEA Updates
After IDEA Steering Committee discussions in January
2013 at the American Society of Clinical Oncology (ASCO)
Gastrointestinal (GI) Symposium (San Francisco, California,
USA) two major decisions were reached.
IDEA analysis plan modification
The committee discussed extensively the need for a revised
analysis plan for IDEA, because of the expectation of fewer
events than planned after three years of follow-up. In the
IDEA design, the critical driver of the analysis timing is the
number of DFS events, given that the precise accrual and
follow-up patterns will differ among the six included studies.
The initial primary IDEA hypothesis was based on two con-
temporary trials, MOSAIC, and NSAPBC07. In these studies,
the number of DFS events after three years has subsequently
been demonstrated to be low (Table 2). In addition, in recent
studies, DFS at three years with FOLFOX4 or mFOLFOX6
has been superior to the assumed 72 % DFS at three years for
six months of FOLFOX or XELOX (Table 2) [1, 2••, 3, 4•,
5••, 6]. As a result, it became clear that the originally planned
noninferiority margin of 1.10 (requiring 4,700 events) would
not be achievable with 90 % power unless follow-up was
extended by several years or sample size increased by several
thousand patients. Neither of these options seemed feasible.
The committee thus considered either reducing the power to
detect noninferiority, or increasing the noninferiority margin.
After discussion, the committee agreed unanimously (one
vote per trial) to amend the target noninferiority margin to
1.12while retaining 90% power to declare noninferiority with
the 1.12 margin. The resulting number of events required
will be 3,400 (reduced from 4,700 in the original plan).
The noninferiority margin of HR=1.12 is equivalent to
a three-year absolute DFS difference of 2.7 % (from 72%
Table 2 Disease-fee survival at
three and five years for stage III
colon cancer treated with
oxaliplatin-based chemotherapy
according to recently reported
studies
NE, not evaluated
Trial Regimen (treatment group) DFS at three years (%) DFS at five years (%)
MOSAIC [1, 2••] FOLFOX4 (experimental) 72.2 66.4
NSABP C-07 [3, 4•] FLOX (experimental) NE 64.4
NO16968 [5••, 6] XELOX (experimental) 70.9 66.1
NSABP C-08 [13•] mFOLFOX6 (control) 72 NE
AVANT [17] FOLFOX4 (control) 76 NE
NCCTG [16] mFOLFOX6 (control) 75 NE
PETACC8 Intergroup [18] FOLFOX4 (control) 78 NE
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to 69.3 %) whereas the previous margin corresponded to a
difference of 2.3 % (72 % vs. 69.7 %). This new number of
events (3,400) seems feasible with two years minimum follow-
up on all patients, resulting in a final analysis most likely in late
2015 or early 2016.
Modification of interim analysis plan
As originally stated, two interim analyses, after 50 %
and 75 % of events, to look for futility to declare
noninferiority were to be performed. The committee
considered moving the analysis schedule ahead to per-
form the interim analyses after 33 % and 66 % of
events. After discussion, this change was not recom-
mended (vote 5–0 with one abstention) because of the
feeling that a boundary at 33 % of events would be too
conservative to be useful. Furthermore, the committee
considered a proposal to drop the second planned inter-
im analysis after 75 % of events. After discussion, this
proposal was adopted by a vote of 4–2, on the basis of
the assumption that when 75 % of events are expected
to occur, all trials are expected to be already closed to
accrual. This proposal will also preserve additional type
I error for the final analysis.
Accrual Update (February 2013)
Six trials are in progress, with one planned to close to
inclusion in March 2013 (TOSCA trial) and five continuing
inclusion (Table 3).
SCOT trial
EudraCT Number: 2007-003957-10
ClinicalTrials.gov Identifier: NCT00749450
Sponsor: NHS Greater Glasgow and Clyde (UK)
Groups: the CACTUS and OCTO
Chemotherapy (regimen): XELOX or mFOLFOX6
Activation date: March 27, 2008
Planned closure: November 2013
Current status: open in the UK, Australia, Denmark,
Spain, Sweden, and New Zealand
Planned accrual: 9,500 patients stage II and III
(original)—4,000 stage III (revised); sites open: 159 centers
open in the UK, 32 in Australia, 7 in Denmark, 19 in Spain, 11
in Sweden, and 4 in New Zealand
Current accrual: 4,919 patients randomized (approxi-
mately 67 percent of patients with stage III colon cancer);
current accrual rate is 136 per month
Sources of funding: Medical Research Council (MRC)
(UK) (ref: G0601705).
http://clinicaltrials.gov/ct2/show/NCT00749450
TOSCA trial
EudraCT Number: 2007-000354-31
ClinicalTrials.gov Identifier: NCT00646607.
Sponsor: Fondazione Gruppo Italiano per lo Studio dei
Carcinomi dell’Apparato Digerente (GISCAD)
Groups : APRIC (Associazione Per la RIcerca
Clinica);GIRCG (Gruppo Italiano Ricerca Cancro Gastrico);
Table 3 Update on patient accrual into the IDEA trial (updated at the end of February 2013)
Trial site Trial Group Current (stage III) Planned accrual
UK, Australia, Denmark, Spain, Sweden,
New Zealand
SCOT CACTUS, OCTO 3,295 4,000
Italy TOSCA GISCAD* 2,389 2,500
France IDEA GERCOR, PRODIGE (FFCD – Unicancer) 1,479 2,000
US 80702 CALGB/SWOG 972 2,500
Greece HORG HORG 432 1,000
Japan ACHIEVE JFMC 230 1,200
Total 6 trials 16 groups 8,797 ≥10,500
SCOT, Short Course Oncology Treatment; TOSCA, Three or Six Colon Adjuvant; IDEA, International Duration Evaluation of Adjuvant Chemotherapy;
CLEAR, Celecoxib and Length of Adjuvant Rx; HORG, Hellenic Oncology Research Group; ACHIEVE, Adjuvant Chemotherapy for colon cancer
with HIgh EVidencE; CACTUS, Cancer Clinical Trials Unit Scotland; OCTO, Oncology Clinical Trials Office, APRIC, Associazione Per la RIcerca
Clinica; GIRCG, Gruppo Italiano Ricerca Cancro Gastrico; *GISCAD and collaborating groups, Gruppo Italiano per lo Studio dei Carcinomi
dell’Apparato Digerente; GOAM, Gruppo Oncologico Aree Metropolitane; GOCSI, Gruppo Oncologico del Centro Sud e lsole; GOCCI, Gruppo
Oncologico Chirurgico Cooperativo Italiano; GOIRC, Gruppo Oncologico Italiano di Ricerca Clinica; GOIM, Gruppo Oncologico Italia Meridionale ;
GONO, Gruppo Oncologico del Nord Ovest; IOR, Istituto Oncologico Romagnolo; ITMO, Italian Trials in Medical Oncology; SICOG, Southern Italy
Cooperative Oncology Group; SICOG, Southern Italy Cooperative Oncology Group; GERCOR, Groupe Coopérateur Multidisciplinaire en Oncologie;
PRODIGE, Partenariat de recherche en oncologie digestive; FFCD, Fédération Francophone de Cancérologie Digestive; CALGB, Cancer and Leukemia
Group B; SWOG, Southwest Oncology Group; JFMC, Japanese Foundation for Multidisciplinary Treatment of Cancer
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GISCAD; GOAM (Gruppo Oncologico Aree Metropolitane);
GOCSI (Gruppo Oncologico del Centro Sud e lsole); GOCCI
(Gruppo Oncologico Chirurgico Cooperativo Italiano); GOIRC
(Gruppo Oncologico Italiano di Ricerca Clinica); GOIM
(Gruppo Oncologico Italia Meridionale); GONO (Gruppo
Oncologico del Nord Ovest); IOR (Istituto Oncologico
Romagnolo); ITMO (Italian Trials in Medical Oncology);
SICOG (Southern Italy Cooperative Oncology Group)
Chemotherapy (regimen): FOLFOX4
Activation date: June 20, 2007
Planned closure: December 2012
Current status: closed in March 2013
Sites open: 130 sites; current accrual: 3,759 patients
(2,389 patients with stage III colon cancer)
Sources of funding: Italian Ministry of Health
http://clinicaltrials.gov/show/NCT00646607
IDEA France
EudraCT Number: 2009-010384-16
ClinicalTrials.gov Identifier: NCT00958737
Sponsor: GERCOR
Groups: PRODIGE (FFCD – FNCLCC) and GERCOR
Chemotherapy (regimen): XELOX or mFOLFOX6
Activation date: May 2, 2009
Current status: open; planned accrual: 2,000 patients;
sites open: 135 open centers; 122 centers enrolled at least
one patient; current accrual: 1,479 patients randomized (all
patients with stage III colon cancer); accrual rate is approx-
imately 45 patients per month
Sources of funding: PHRC National Cancer 2009 and
Institut National du cancer (French National Cancer Institute)
Others: Tissue and blood collection is ongoing
http://clinicaltrials.gov/ct2/show/NCT00958737?term=
idea&rank=3
CALGB/SWOG Colon Trial C80702
ClinicalTrials.gov Identifier: NCT01150045
Sponsor: CALGB
Groups: SWOG and CALGB
Chemotherapy (regimen): mFOLFOX6
Activation date: July 2010
Current status: open
Planned accrual: 2,500 patients
Sites open: 588 sites are listed in ClinicalTrials.gov –
endorsed by all adult oncology treatment cooperative groups
in the US and Canada
Current accrual: 972 patients with stage III, current ac-
crual rate is 45 patients per month
Sources of funding: Cancer Therapy Evaluation Program
(CTEP) by National Cancer Institute; Pfizer Oncology is
providing celecoxib and placebo.
http://clinicaltrials.gov/ct2/show/NCT01150045?term=
celecoxib&rank=91
HORG trial
ClinicalTrials.gov Identifier: NCT01308086
Sponsor and Group: HORG group
Chemotherapy (regimen): XELOX or FOLFOX4
Activation date: October 2010
Current status: open;
Planned accrual: 1,000 patients
Sites open: 15 sites have been activated (15 have at least
one patient enrolled)
Current accrual: 569 patients (382 patients with stage III
cancer); accrual rate is 33 patients per month for last three
months
Sources of funding: HORG group.
ACHIEVE trial, JFMC 47-1202-C3
UMIN-CTR Clinical Trial Identifier: UMIN000008543
Sponsor and Groups: Japanese Foundation for Multidis-
ciplinary Treatment of Cancer (JFMC)
Chemotherapy (regimen): XELOX or mFOLFOX6
Activation date: August 1, 2012
Current status: open
Planned accrual: 1,200 patients; target accrual is 50 pa-
tients per month once all sites are open; Sites open: 52 sites
open, goal is to have 440 total sites
Current accrual: 230 patients with stage III colon cancer
Sources of funding: JFMC under contract with Yakult
Honsha
https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?func-
tion=brows&action=brows&type=summary&recptno=
R000010043&language=E
The total accrual in February 2013 for the six IDEA trials
reached 8797 patients. A sample size of 10,500 patients is
projected by the end of 2013. Given that accrual extending
beyond the planned accrual will lead to higher number of
DFS events and will enable earlier definitive analysis, all
trials are encouraged to continue accrual as long as possible.
Discussion and Conclusions
The IDEA collaboration is a new model for international
collaboration with six trials accruing patients and combined
accrual, as of February 2013, surpassing 8,500 stage III
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colon cancer patients. Five of the six trials within the IDEA
collaboration are actively accruing patients (Table 2) with
worldwide accrual continuing to exceed 250 patients per
month. If all trials continue at their current pace, the collab-
oration remains on track to achieve and probably exceed the
accrual objective of 10,500 patients before the end of 2013.
The IDEA collaboration is a unique example of academic
international collaboration, with the objective of reducing treat-
ment duration, toxicity, and cost of adjuvant therapy in colon
cancer. Conventional chemotherapy is administered for six
months and is associated with a clinically relevant risk of
long-term neurotoxicity. Therefore, the type of study proposed
here is extremely important for improving the quality of life of
patients who suffer from colorectal cancer. One major issue of
the IDEA collaboration is to reduce cumulative, potential long-
lasting neuropathy. In the MOSAIC study, 48 months after the
end of chemotherapy, grade 1, 2, and 3 peripheral sensory
neuropathy was observed in 11.9 %, 2.8 %, and 0.7 % of the
patients examined, respectively. A reduction of adjuvant che-
motherapy to less than six months has proved effective for
other cancers, for example breast and testicular cancer, and
was better tolerated by patients in clinical practice [14, 15].
The question about optimum duration of adjuvant therapy in
breast cancer was recently addressed in the Cancer and Leuke-
miaGroupB (CALGB) 40101 phase III trial [14]. The CALGB
40101 trial enrolled 3,171 women with operable primary breast
cancer and zero to three positive nodes between 2002 and 2008.
Patients were randomized to receive doxorubicin and cyclo-
phosphamide (four or six cycles) or paclitaxel (four or six
cycles). Multivariate proportional hazards modeling showed
that six cycles of treatment was not superior to four cycles for
either relapse-free or OS after adjustment for tumor size, num-
ber of positive nodes, hormone receptor status, and menopausal
status. Not unexpectedly, more toxicity was observed with six
cycles of therapy. This crucial study confirmed that shorter
duration of chemotherapy for early stage breast cancer should
be considered as standard of care [14].
Targeted therapy has been developed as single-agent che-
motherapy, but a target is part of a complex network of in-
teractions with multiple targets [13•, 16–18]. Recent studies
indicate that adjuvant use of targeted therapy may not involve
chemotherapy, at least in the context of currently available
targeted therapy (bevacizumab or cetuximab). However, it
might be possible to study sequential treatment, for example
chemotherapy followed by targeted therapy.
FOLFOX4 was administrated only in the TOSCA and
HORG trials. In the four other studies, only two regimens
were used, mFOLFOX6 and XELOX. mFOLFOX6 was
preferred to the validated FOLFOX4 regimen, because the
mFOLFOX6 regimen is more convenient than FOLFOX4
for the patient and less expensive: one day vs. two days in the
out-patient unit without evidence of further toxicity resulting
from the increased dose of 5-FU. No study has directly
compared FOLFOX4 with mFOLFOX6 in an adjuvant set-
ting. However the three-year DFS in the standard group
(mFOLFOX6) of the NSABP C-08 study and the NCCTG
study N0147 was at least comparable with that observed in
patients treated with FOLFOX4 in the MOSAIC and
AVANT studies (Table 2) [1, 2••, 13•, 16–18].
The IDEA Steering Committee and gastrointestinal investi-
gators worldwide are clearly committed to providing a defini-
tive answer to the primary IDEA hypothesis that three months
of FOLFOX or XELOX therapy is non-inferior to the standard
six-month regimen. The IDEA Steering Committee wishes to
sincerely thank all IDEA investigators, staff, and most impor-
tantly, patients, who are contributing to this international effort.
IDEA’s success is a testimony to the outstanding collaborative
nature of gastrointestinal cancer investigators worldwide.
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